在老年人和免疫功能低下的患者中使用PD-1抑制剂,患有晚期或转移性皮肤状细胞癌
Alexander Yakobson1, Ashraf Abu Jama1, Omar Abu Saleh2
1The Legacy Heritage Cancer Center & Dr. Larry Norton Institute, Soroka Medical Center, Ben Gurion University, Beer Sheva 84105, Israel.
Cancers
|August 26, 2023
概括
塞米普利马布和潘布罗利祖马布在治疗75岁以上老年患者的晚期皮肤癌 (cSCC) 中表现出有效性. 这些免疫疗法在这个脆弱人群中显示出可接受的安全性.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 免疫治疗是一种免疫疗法.
背景情况:
- 皮肤状细胞癌 (cSCC) 是一种常见的皮肤癌,衰老和紫外线暴露是主要的危险因素.
- 塞米普利马布和潘布罗利祖马布已被批准用于高级cSCC,但临床试验排除了老年人和免疫受损患者.
研究的目的:
- 评估塞米普利马布和潘布罗利祖马布在老年人 (75岁以上) 免疫功能低下和免疫能力强的患者的疗效和安全性,这些患者患有局部晚期或转移性cSCC.
主要方法:
- 追溯性研究包括局部晚期或转移性cSCC的老年患者,他们接受了CEMIPLIMAB或PEMBROLIZUMAB治疗.
- 随访时间中位数为35.6个月;分析无进展生存率,反应率和不良事件.
主要成果:
- 无进展生存时间的中位数为8.94个月.
- 疾病控制率为91.4%,完全响应率为17.1%,部分响应率为51.4%.
- 与治疗相关的不良事件发生在85.6%的患者中,大多数为1-2级.
结论:
- 塞米普利马布和潘布罗利祖马布是治疗老年患者局部晚期或转移性cSCC的有效治疗方法.
- 这些免疫疗法在这个特定的患者群体中表现出可接受的安全性.
相关概念视频
Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


